Cargando…

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project

INTRODUCTION: Patients with refractory metastatic cancer have been shown to benefit from molecular profiling of tumor tissue. The ONCO-T-PROFILE project was launched in March 2014 at the Innsbruck Medical University. Within 2 years our project aims to recruit 110 patients with stage IV cancer refrac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seeber, Andreas, Gastl, Guenther, Ensinger, Christian, Spizzo, Gilbert, Willenbacher, Wolfgang, Kocher, Florian, Leitner, Christoph, Willenbacher, Ella, Amann, Arno, Steiner, Normann, Eisterer, Wolfgang, Voss, Andreas, Russell, Kenneth, Zwierzina, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115171/ https://www.ncbi.nlm.nih.gov/pubmed/28050231 http://dx.doi.org/10.18632/genesandcancer.121

Ejemplares similares

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies
por: Zimmer, Kai, et al.
Publicado: (2019)

Curcumin: New Insights into an Ancient Ingredient against Cancer
por: Willenbacher, Ella, et al.
Publicado: (2019)

Erratum: Willenbacher, E., et al. Curcumin: New Insights into an Ancient Ingredient against Cancer. Int. J. Mol. Sci. 2019, 20, 1808
por: Willenbacher, Ella, et al.
Publicado: (2020)

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment
por: Spizzo, Gilbert, et al.
Publicado: (2019)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia
por: Willenbacher, Ella, et al.
Publicado: (2019)

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014)

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis
por: Spizzo, Gilbert, et al.
Publicado: (2011)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015)

Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
por: Martowicz, Agnieszka, et al.
Publicado: (2012)

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

Molecular profile of BRCA-mutated biliary tract cancers
por: Spizzo, Gilbert, et al.
Publicado: (2020)

Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study
por: Lehmann, Jens, et al.
Publicado: (2023)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial‐to‐Mesenchymal Transition
por: Boesch, Maximilian, et al.
Publicado: (2018)

Challenges in Rheological Characterization of Highly Concentrated Suspensions — A Case Study for Screen-printing Silver Pastes
por: Yüce, Ceren, et al.
Publicado: (2017)

Infiltration of immune cells into cancer cell/stroma cell 3D microtissues
por: Koeck, Stefan, et al.
Publicado: (2015)

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth
por: Martowicz, Agnieszka, et al.
Publicado: (2013)

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
por: Kocher, Florian, et al.
Publicado: (2021)

The profile of the onco-hematology patient in the palliative care: 4 years of experience
por: Couto, Maria Eduarda, et al.
Publicado: (2019)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Highly conductive, printable pastes from capillary suspensions
por: Schneider, Monica, et al.
Publicado: (2016)

Effect of Polymeric Binders on Dispersion of Active Particles in Aqueous LiFePO(4)-Based Cathode Slurries as well as on Mechanical and Electrical Properties of Corresponding Dry Layers
por: Gordon, Ronald, et al.
Publicado: (2020)

Development of a 3D angiogenesis model to study tumour – endothelial cell interactions and the effects of anti-angiogenic drugs
por: Amann, Arno, et al.
Publicado: (2017)

Immunogenicity profile after COVID-19 vaccination in patients with onco-hematological diseases
por: de Almeida, João Bosco, et al.
Publicado: (2023)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
por: Lanser, Lukas, et al.
Publicado: (2020)

Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient‐reported outcome assessment for the Austrian Myelome Registry
por: Sztankay, Monika, et al.
Publicado: (2019)

OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis
por: Xu, Quan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2e1rj677fp5vu3i9tjr15aigca